Teijin Pharma grants exclusive license to Bioprojet
Japan-based Teijin Group’s (TYO: 3401) healthcare business, Teijin Pharma, has entered into an exclusive global licensing agreement with French drugmaker Bioprojet Pharma.
Under the terms of the agreement, Teijin Pharma grants Bioprojet exclusive worldwide rights to research, develop, manufacture and commercialize an investigational candidate for narcolepsy. Shares of the parent company closed up 3.8% at 1,500 yen following the announcement.
The investigational candidate is a highly potent and selective orexin 2 receptor agonist discovered at the Teijin Institute for Bio-medical Research in Tokyo. The candidate is expected to compensate for a deficiency in orexins, brain peptides that help sustain alertness and prevent rapid eye movement (REM) sleep from occurring at the wrong times. The mechanism of action (MoA) of this class of compounds has been demonstrated and could represent the next novel MoA for the treatment of narcolepsy and other sleep/wake disorders.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze